Effect of Whole Bone Marrow Cell Infusion in the Progression of Experimental Chronic Renal Failure

Abstract Introduction The therapeutic potential of adult stem cells for the treatment of chronic diseases is becoming increasingly evident over the last few years. In the present study, we sought to assess whether the infusion of bone marrow–derived mononuclear cells (MoSCs) and mesenchymal cells (M...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Transplantation proceedings 2008-04, Vol.40 (3), p.853-855
Hauptverfasser: Caldas, H.C, Fernandes, I.M.M, Gerbi, F, Souza, A.C, Baptista, M.A.S.F, Ramalho, H.J, Kawasaki-Oyama, R.S, Goloni-Bertollo, E.M, Pavarino-Bertelli, E.C, Braile, D.M, Abbud-Filho, M
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 855
container_issue 3
container_start_page 853
container_title Transplantation proceedings
container_volume 40
creator Caldas, H.C
Fernandes, I.M.M
Gerbi, F
Souza, A.C
Baptista, M.A.S.F
Ramalho, H.J
Kawasaki-Oyama, R.S
Goloni-Bertollo, E.M
Pavarino-Bertelli, E.C
Braile, D.M
Abbud-Filho, M
description Abstract Introduction The therapeutic potential of adult stem cells for the treatment of chronic diseases is becoming increasingly evident over the last few years. In the present study, we sought to assess whether the infusion of bone marrow–derived mononuclear cells (MoSCs) and mesenchymal cells (MSCs) could reduce/stabilize the rate of progression of chronic renal failure (CRF) in rats. Methods We used the 5/6 renal mass reduction model to induce chronic renal failure in male Wistar rats. Renal function was assessed by measurements of serum creatinine (sCr), creatinine clearance (Clcr), and 24-hour proteinuria at baseline as well as 60 and 120 days after surgery. MoSCs and MSCs obtained from bone marrow aspirates were separated by the Ficoll-Hypaque method. After a 12- to 14-day culture, 1.5 × 106 MSCs and the same number of MoSCs were injected into the renal parenchyma of the remanant kidney of rats with CRF on the day of surgery. Results Among the control group, at day 120, the results were sCr = 1.31 ± 0.5 mg/dL, Clcr = 0.64 ± 0.35 mL/min, and proteinuria = 140.0 ± 57.7 mg/24 h. Rats treated with MoSCs at day 120 had sCr = 0.81 ± 0.20 mg/dL, Clcr = 1.05 ± 0.26 mL/min, and proteinuria = 61 ± 46.5 mg/24 h, while rats injected with MSCs had sCr = 0.95 ± 0.1 mg/dL, Clcr = 0.68 ± 0.24 mL/min, and proteinuria = 119.2 ± 50.0 mg/24 h. Analysis of the progression to CRF showed that the treatment significantly reduced the rate of decline in Clcr after treatment with MoSc: control: −0.0049 ± 0.0024 mL/min/d versus MSC: − 0.0013 ± 0.0017 mL/min/d versus MoSC: +0.0002 ± 0.0016 mL/min/d ( P = .017). Proteinuria tended to be lower among the treated groups. Histological scores of chronic damage were not different, but distinct patterns of chronic lesions were observed among treated rats. Conclusion Our results showed that progression of CRF in rats could be slowed/stabilized by intrarenal parenchymal injection of MoSCs. A trend toward reduction in the progression rate of CRF was also observed with injection of MSCs.
doi_str_mv 10.1016/j.transproceed.2008.03.009
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_69178509</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0041134508002121</els_id><sourcerecordid>69178509</sourcerecordid><originalsourceid>FETCH-LOGICAL-c463t-f2d1b836c4f86d21ad03a7addf7e2d9a09e5586d8dd670019570b14c3636cfc3</originalsourceid><addsrcrecordid>eNqNksFuEzEQhi0EomnhFZCFBLcNY3vXu8sBqaQpVCoCQSWOlmOPicPGDvYu0LfHaaIKceJkjef7x55_hpDnDOYMmHy1mY9Jh7xL0SDaOQfo5iDmAP0DMmNdKyouuXhIZgA1q5iomxNymvMGSsxr8ZicsK5uGhDNjKyWzqEZaXT06zoOSN_GgPSDTin-ogscBnoV3JR9DNQHOq6RfkrxW8J8d1VUy987TH6LYdQDXaxTDN7QzxhKdKn9MCV8Qh45PWR8ejzPyM3l8mbxvrr--O5qcX5dmVqKsXLcslUnpKldJy1n2oLQrbbWtchtr6HHpimZzlrZArC-aWHFaiNk0TgjzsjLQ9niy48J86i2PpvSgQ4Yp6xkz9qugb6Arw-gSTHnhE7tSgM63SoGam-w2qi_DVZ7gxUIBXfiZ8dXptW25O6lR0cL8OII6Gz04Eoh4_M9x0F0tZSscBcHDoslPz0mlY3HYND6VAaibPT_9583_5Qxgy8j0MN3vMW8iVMqo8iKqcwVqC_7ldhvBHQAnHEm_gBlGLVw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>69178509</pqid></control><display><type>article</type><title>Effect of Whole Bone Marrow Cell Infusion in the Progression of Experimental Chronic Renal Failure</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Caldas, H.C ; Fernandes, I.M.M ; Gerbi, F ; Souza, A.C ; Baptista, M.A.S.F ; Ramalho, H.J ; Kawasaki-Oyama, R.S ; Goloni-Bertollo, E.M ; Pavarino-Bertelli, E.C ; Braile, D.M ; Abbud-Filho, M</creator><creatorcontrib>Caldas, H.C ; Fernandes, I.M.M ; Gerbi, F ; Souza, A.C ; Baptista, M.A.S.F ; Ramalho, H.J ; Kawasaki-Oyama, R.S ; Goloni-Bertollo, E.M ; Pavarino-Bertelli, E.C ; Braile, D.M ; Abbud-Filho, M</creatorcontrib><description>Abstract Introduction The therapeutic potential of adult stem cells for the treatment of chronic diseases is becoming increasingly evident over the last few years. In the present study, we sought to assess whether the infusion of bone marrow–derived mononuclear cells (MoSCs) and mesenchymal cells (MSCs) could reduce/stabilize the rate of progression of chronic renal failure (CRF) in rats. Methods We used the 5/6 renal mass reduction model to induce chronic renal failure in male Wistar rats. Renal function was assessed by measurements of serum creatinine (sCr), creatinine clearance (Clcr), and 24-hour proteinuria at baseline as well as 60 and 120 days after surgery. MoSCs and MSCs obtained from bone marrow aspirates were separated by the Ficoll-Hypaque method. After a 12- to 14-day culture, 1.5 × 106 MSCs and the same number of MoSCs were injected into the renal parenchyma of the remanant kidney of rats with CRF on the day of surgery. Results Among the control group, at day 120, the results were sCr = 1.31 ± 0.5 mg/dL, Clcr = 0.64 ± 0.35 mL/min, and proteinuria = 140.0 ± 57.7 mg/24 h. Rats treated with MoSCs at day 120 had sCr = 0.81 ± 0.20 mg/dL, Clcr = 1.05 ± 0.26 mL/min, and proteinuria = 61 ± 46.5 mg/24 h, while rats injected with MSCs had sCr = 0.95 ± 0.1 mg/dL, Clcr = 0.68 ± 0.24 mL/min, and proteinuria = 119.2 ± 50.0 mg/24 h. Analysis of the progression to CRF showed that the treatment significantly reduced the rate of decline in Clcr after treatment with MoSc: control: −0.0049 ± 0.0024 mL/min/d versus MSC: − 0.0013 ± 0.0017 mL/min/d versus MoSC: +0.0002 ± 0.0016 mL/min/d ( P = .017). Proteinuria tended to be lower among the treated groups. Histological scores of chronic damage were not different, but distinct patterns of chronic lesions were observed among treated rats. Conclusion Our results showed that progression of CRF in rats could be slowed/stabilized by intrarenal parenchymal injection of MoSCs. A trend toward reduction in the progression rate of CRF was also observed with injection of MSCs.</description><identifier>ISSN: 0041-1345</identifier><identifier>EISSN: 1873-2623</identifier><identifier>DOI: 10.1016/j.transproceed.2008.03.009</identifier><identifier>PMID: 18455035</identifier><identifier>CODEN: TRPPA8</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Animals ; Biological and medical sciences ; Bone Marrow Transplantation - methods ; Creatinine - blood ; Creatinine - metabolism ; Disease Models, Animal ; Disease Progression ; Fundamental and applied biological sciences. Psychology ; Fundamental immunology ; Kidney Failure, Chronic - surgery ; Leukocyte Transfusion ; Leukocytes, Mononuclear ; Male ; Medical sciences ; Mesoderm - cytology ; Mesoderm - transplantation ; Nephrology. Urinary tract diseases ; Nephropathies. Renovascular diseases. Renal failure ; Rats ; Rats, Wistar ; Renal failure ; Surgery ; Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases ; Tissue, organ and graft immunology</subject><ispartof>Transplantation proceedings, 2008-04, Vol.40 (3), p.853-855</ispartof><rights>Elsevier Inc.</rights><rights>2008 Elsevier Inc.</rights><rights>2008 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c463t-f2d1b836c4f86d21ad03a7addf7e2d9a09e5586d8dd670019570b14c3636cfc3</citedby><cites>FETCH-LOGICAL-c463t-f2d1b836c4f86d21ad03a7addf7e2d9a09e5586d8dd670019570b14c3636cfc3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0041134508002121$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>309,310,314,776,780,785,786,3537,23909,23910,25118,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=20384661$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18455035$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Caldas, H.C</creatorcontrib><creatorcontrib>Fernandes, I.M.M</creatorcontrib><creatorcontrib>Gerbi, F</creatorcontrib><creatorcontrib>Souza, A.C</creatorcontrib><creatorcontrib>Baptista, M.A.S.F</creatorcontrib><creatorcontrib>Ramalho, H.J</creatorcontrib><creatorcontrib>Kawasaki-Oyama, R.S</creatorcontrib><creatorcontrib>Goloni-Bertollo, E.M</creatorcontrib><creatorcontrib>Pavarino-Bertelli, E.C</creatorcontrib><creatorcontrib>Braile, D.M</creatorcontrib><creatorcontrib>Abbud-Filho, M</creatorcontrib><title>Effect of Whole Bone Marrow Cell Infusion in the Progression of Experimental Chronic Renal Failure</title><title>Transplantation proceedings</title><addtitle>Transplant Proc</addtitle><description>Abstract Introduction The therapeutic potential of adult stem cells for the treatment of chronic diseases is becoming increasingly evident over the last few years. In the present study, we sought to assess whether the infusion of bone marrow–derived mononuclear cells (MoSCs) and mesenchymal cells (MSCs) could reduce/stabilize the rate of progression of chronic renal failure (CRF) in rats. Methods We used the 5/6 renal mass reduction model to induce chronic renal failure in male Wistar rats. Renal function was assessed by measurements of serum creatinine (sCr), creatinine clearance (Clcr), and 24-hour proteinuria at baseline as well as 60 and 120 days after surgery. MoSCs and MSCs obtained from bone marrow aspirates were separated by the Ficoll-Hypaque method. After a 12- to 14-day culture, 1.5 × 106 MSCs and the same number of MoSCs were injected into the renal parenchyma of the remanant kidney of rats with CRF on the day of surgery. Results Among the control group, at day 120, the results were sCr = 1.31 ± 0.5 mg/dL, Clcr = 0.64 ± 0.35 mL/min, and proteinuria = 140.0 ± 57.7 mg/24 h. Rats treated with MoSCs at day 120 had sCr = 0.81 ± 0.20 mg/dL, Clcr = 1.05 ± 0.26 mL/min, and proteinuria = 61 ± 46.5 mg/24 h, while rats injected with MSCs had sCr = 0.95 ± 0.1 mg/dL, Clcr = 0.68 ± 0.24 mL/min, and proteinuria = 119.2 ± 50.0 mg/24 h. Analysis of the progression to CRF showed that the treatment significantly reduced the rate of decline in Clcr after treatment with MoSc: control: −0.0049 ± 0.0024 mL/min/d versus MSC: − 0.0013 ± 0.0017 mL/min/d versus MoSC: +0.0002 ± 0.0016 mL/min/d ( P = .017). Proteinuria tended to be lower among the treated groups. Histological scores of chronic damage were not different, but distinct patterns of chronic lesions were observed among treated rats. Conclusion Our results showed that progression of CRF in rats could be slowed/stabilized by intrarenal parenchymal injection of MoSCs. A trend toward reduction in the progression rate of CRF was also observed with injection of MSCs.</description><subject>Animals</subject><subject>Biological and medical sciences</subject><subject>Bone Marrow Transplantation - methods</subject><subject>Creatinine - blood</subject><subject>Creatinine - metabolism</subject><subject>Disease Models, Animal</subject><subject>Disease Progression</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Fundamental immunology</subject><subject>Kidney Failure, Chronic - surgery</subject><subject>Leukocyte Transfusion</subject><subject>Leukocytes, Mononuclear</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Mesoderm - cytology</subject><subject>Mesoderm - transplantation</subject><subject>Nephrology. Urinary tract diseases</subject><subject>Nephropathies. Renovascular diseases. Renal failure</subject><subject>Rats</subject><subject>Rats, Wistar</subject><subject>Renal failure</subject><subject>Surgery</subject><subject>Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases</subject><subject>Tissue, organ and graft immunology</subject><issn>0041-1345</issn><issn>1873-2623</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNksFuEzEQhi0EomnhFZCFBLcNY3vXu8sBqaQpVCoCQSWOlmOPicPGDvYu0LfHaaIKceJkjef7x55_hpDnDOYMmHy1mY9Jh7xL0SDaOQfo5iDmAP0DMmNdKyouuXhIZgA1q5iomxNymvMGSsxr8ZicsK5uGhDNjKyWzqEZaXT06zoOSN_GgPSDTin-ogscBnoV3JR9DNQHOq6RfkrxW8J8d1VUy987TH6LYdQDXaxTDN7QzxhKdKn9MCV8Qh45PWR8ejzPyM3l8mbxvrr--O5qcX5dmVqKsXLcslUnpKldJy1n2oLQrbbWtchtr6HHpimZzlrZArC-aWHFaiNk0TgjzsjLQ9niy48J86i2PpvSgQ4Yp6xkz9qugb6Arw-gSTHnhE7tSgM63SoGam-w2qi_DVZ7gxUIBXfiZ8dXptW25O6lR0cL8OII6Gz04Eoh4_M9x0F0tZSscBcHDoslPz0mlY3HYND6VAaibPT_9583_5Qxgy8j0MN3vMW8iVMqo8iKqcwVqC_7ldhvBHQAnHEm_gBlGLVw</recordid><startdate>20080401</startdate><enddate>20080401</enddate><creator>Caldas, H.C</creator><creator>Fernandes, I.M.M</creator><creator>Gerbi, F</creator><creator>Souza, A.C</creator><creator>Baptista, M.A.S.F</creator><creator>Ramalho, H.J</creator><creator>Kawasaki-Oyama, R.S</creator><creator>Goloni-Bertollo, E.M</creator><creator>Pavarino-Bertelli, E.C</creator><creator>Braile, D.M</creator><creator>Abbud-Filho, M</creator><general>Elsevier Inc</general><general>Elsevier Science</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20080401</creationdate><title>Effect of Whole Bone Marrow Cell Infusion in the Progression of Experimental Chronic Renal Failure</title><author>Caldas, H.C ; Fernandes, I.M.M ; Gerbi, F ; Souza, A.C ; Baptista, M.A.S.F ; Ramalho, H.J ; Kawasaki-Oyama, R.S ; Goloni-Bertollo, E.M ; Pavarino-Bertelli, E.C ; Braile, D.M ; Abbud-Filho, M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c463t-f2d1b836c4f86d21ad03a7addf7e2d9a09e5586d8dd670019570b14c3636cfc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Animals</topic><topic>Biological and medical sciences</topic><topic>Bone Marrow Transplantation - methods</topic><topic>Creatinine - blood</topic><topic>Creatinine - metabolism</topic><topic>Disease Models, Animal</topic><topic>Disease Progression</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Fundamental immunology</topic><topic>Kidney Failure, Chronic - surgery</topic><topic>Leukocyte Transfusion</topic><topic>Leukocytes, Mononuclear</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Mesoderm - cytology</topic><topic>Mesoderm - transplantation</topic><topic>Nephrology. Urinary tract diseases</topic><topic>Nephropathies. Renovascular diseases. Renal failure</topic><topic>Rats</topic><topic>Rats, Wistar</topic><topic>Renal failure</topic><topic>Surgery</topic><topic>Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases</topic><topic>Tissue, organ and graft immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Caldas, H.C</creatorcontrib><creatorcontrib>Fernandes, I.M.M</creatorcontrib><creatorcontrib>Gerbi, F</creatorcontrib><creatorcontrib>Souza, A.C</creatorcontrib><creatorcontrib>Baptista, M.A.S.F</creatorcontrib><creatorcontrib>Ramalho, H.J</creatorcontrib><creatorcontrib>Kawasaki-Oyama, R.S</creatorcontrib><creatorcontrib>Goloni-Bertollo, E.M</creatorcontrib><creatorcontrib>Pavarino-Bertelli, E.C</creatorcontrib><creatorcontrib>Braile, D.M</creatorcontrib><creatorcontrib>Abbud-Filho, M</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Transplantation proceedings</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Caldas, H.C</au><au>Fernandes, I.M.M</au><au>Gerbi, F</au><au>Souza, A.C</au><au>Baptista, M.A.S.F</au><au>Ramalho, H.J</au><au>Kawasaki-Oyama, R.S</au><au>Goloni-Bertollo, E.M</au><au>Pavarino-Bertelli, E.C</au><au>Braile, D.M</au><au>Abbud-Filho, M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effect of Whole Bone Marrow Cell Infusion in the Progression of Experimental Chronic Renal Failure</atitle><jtitle>Transplantation proceedings</jtitle><addtitle>Transplant Proc</addtitle><date>2008-04-01</date><risdate>2008</risdate><volume>40</volume><issue>3</issue><spage>853</spage><epage>855</epage><pages>853-855</pages><issn>0041-1345</issn><eissn>1873-2623</eissn><coden>TRPPA8</coden><abstract>Abstract Introduction The therapeutic potential of adult stem cells for the treatment of chronic diseases is becoming increasingly evident over the last few years. In the present study, we sought to assess whether the infusion of bone marrow–derived mononuclear cells (MoSCs) and mesenchymal cells (MSCs) could reduce/stabilize the rate of progression of chronic renal failure (CRF) in rats. Methods We used the 5/6 renal mass reduction model to induce chronic renal failure in male Wistar rats. Renal function was assessed by measurements of serum creatinine (sCr), creatinine clearance (Clcr), and 24-hour proteinuria at baseline as well as 60 and 120 days after surgery. MoSCs and MSCs obtained from bone marrow aspirates were separated by the Ficoll-Hypaque method. After a 12- to 14-day culture, 1.5 × 106 MSCs and the same number of MoSCs were injected into the renal parenchyma of the remanant kidney of rats with CRF on the day of surgery. Results Among the control group, at day 120, the results were sCr = 1.31 ± 0.5 mg/dL, Clcr = 0.64 ± 0.35 mL/min, and proteinuria = 140.0 ± 57.7 mg/24 h. Rats treated with MoSCs at day 120 had sCr = 0.81 ± 0.20 mg/dL, Clcr = 1.05 ± 0.26 mL/min, and proteinuria = 61 ± 46.5 mg/24 h, while rats injected with MSCs had sCr = 0.95 ± 0.1 mg/dL, Clcr = 0.68 ± 0.24 mL/min, and proteinuria = 119.2 ± 50.0 mg/24 h. Analysis of the progression to CRF showed that the treatment significantly reduced the rate of decline in Clcr after treatment with MoSc: control: −0.0049 ± 0.0024 mL/min/d versus MSC: − 0.0013 ± 0.0017 mL/min/d versus MoSC: +0.0002 ± 0.0016 mL/min/d ( P = .017). Proteinuria tended to be lower among the treated groups. Histological scores of chronic damage were not different, but distinct patterns of chronic lesions were observed among treated rats. Conclusion Our results showed that progression of CRF in rats could be slowed/stabilized by intrarenal parenchymal injection of MoSCs. A trend toward reduction in the progression rate of CRF was also observed with injection of MSCs.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>18455035</pmid><doi>10.1016/j.transproceed.2008.03.009</doi><tpages>3</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0041-1345
ispartof Transplantation proceedings, 2008-04, Vol.40 (3), p.853-855
issn 0041-1345
1873-2623
language eng
recordid cdi_proquest_miscellaneous_69178509
source MEDLINE; Elsevier ScienceDirect Journals
subjects Animals
Biological and medical sciences
Bone Marrow Transplantation - methods
Creatinine - blood
Creatinine - metabolism
Disease Models, Animal
Disease Progression
Fundamental and applied biological sciences. Psychology
Fundamental immunology
Kidney Failure, Chronic - surgery
Leukocyte Transfusion
Leukocytes, Mononuclear
Male
Medical sciences
Mesoderm - cytology
Mesoderm - transplantation
Nephrology. Urinary tract diseases
Nephropathies. Renovascular diseases. Renal failure
Rats
Rats, Wistar
Renal failure
Surgery
Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases
Tissue, organ and graft immunology
title Effect of Whole Bone Marrow Cell Infusion in the Progression of Experimental Chronic Renal Failure
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-11T20%3A20%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effect%20of%20Whole%20Bone%20Marrow%20Cell%20Infusion%20in%20the%20Progression%20of%20Experimental%20Chronic%20Renal%20Failure&rft.jtitle=Transplantation%20proceedings&rft.au=Caldas,%20H.C&rft.date=2008-04-01&rft.volume=40&rft.issue=3&rft.spage=853&rft.epage=855&rft.pages=853-855&rft.issn=0041-1345&rft.eissn=1873-2623&rft.coden=TRPPA8&rft_id=info:doi/10.1016/j.transproceed.2008.03.009&rft_dat=%3Cproquest_cross%3E69178509%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=69178509&rft_id=info:pmid/18455035&rft_els_id=1_s2_0_S0041134508002121&rfr_iscdi=true